Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 15, Issue 4, 2006, Pages 173-177

  Ferkolj, Ivan ^a   Hočevar, Alojzija ^a   Golouh, Rastko ^b   Voljč, Mateja Dolenc ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Crohn's disease; Infliximab; Pyoderma gangrenosum

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHYLPREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; PYODERMA GANGRENOSUM; SKIN BIOPSY; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; PYODERMA GANGRENOSUM; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846152295     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003; 30: 97-107.
2. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-83.
3. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-9.
4. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004; 6: 88-90.
5. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005; 19: 603-4
6. Conrad C, Trueb RM. Pyoderma gangrenosum. J Dtsch Dermatol Ges 2005; 3: 334-42.
7. Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986; 13: 323-30.
8. Hunvitz RM, Haseman JH. The evolution of pyoderma gangrenosum. A clinicopathologic correlation. Am J Dermatopathol 1993; 15: 28-33.
9. Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005; 34: 387-91.
10. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase and apoptosis. J Immunol 2000; 165: 5962-9.
11. Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera M, Ricevuti L, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-7.
12. Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250-9.